Previous 10 | Next 10 |
2024-02-14 14:48:35 ET More on BRCC, Evolent Health, etc. V.F. Corporation: Struggles, Failure Risks, But Glimmers Of A Turnaround V.F. Corporation (VFC) Q3 2024 Earnings Call Transcript V.F. Corporation: The Reasons Why We Do Not Want To Own The Stock In 2024 ...
Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy PR Newswire Experts in diabetes, pain and health services from the Worldwide Initiative for Diabetes Education recommend spinal...
Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024 PR Newswire REDWOOD CITY, Calif. , Jan. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering compreh...
(NewsDirect) Investors eyeing dynamic opportunities in healthcare should take note of the burgeoning growth anticipated in the spinal cord injury market. Projections for robust advancements, driven by enhanced diagnosis and increased global healthcare spending, signal a lucrative trajectory f...
Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy PR Newswire Spinal Cord Stimulation Coverage Policy to Include 43 Million Additional Covered Lives REDWOOD CITY, Calif. , Jan. 18, 2024 /PRNe...
Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting PR Newswire Presentations review clinical results of 10 kHz Therapy™ for the treatment of chronic back and leg pain, non-surgical back pain (NSBP), and ...
2024-01-12 11:01:35 ET More on Entheon Biomedical Corp., Nevro, etc. Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript) Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade) Regeneron Pharmaceuticals In...
2024-01-12 06:45:03 ET Truist Financial analyst issues SECTOR PERFORM recommendation for NVRO on January 12, 2024 07:00AM ET. The previous analyst recommendation was Sector Perform. NVRO was trading at $18.72 at issue of the analyst recommendation. The overall analyst co...
2024-01-09 09:02:54 ET More on Nevro Nevro Corp. (NVRO) Q3 2023 Earnings Call Transcript Canaccord cuts Nevro to hold, citing increased competition Nevro gains after activist Engaged discloses stake Seeking Alpha’s Quant Rating on Nevro Histori...
Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results PR Newswire Fourth-Quarter 2023 Worldwide Revenue Exceeds Company's Expectations Announces Restructuring to Support Company's Long-Term Growth and Profitability REDWOOD CITY, Calif....
News, Short Squeeze, Breakout and More Instantly...
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024 PR Newswire REDWOOD CITY, Calif. , April 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changi...
2024-04-11 08:00:08 ET Anthony Petrone from Mizuho Securities issued a price target of $16.00 for NVRO on 2024-04-11 07:03:00. The adjusted price target was set to $16.00. At the time of the announcement, NVRO was trading at $13.28. The overall price target consensus is ...
2024-03-14 13:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...